1
|
Karalus W, Subharat S, Orbell G, Vaatstra B, Munday JS. Equine sarcoids: A clinicopathologic study of 49 cases, with mitotic count and clinical type predictive of recurrence. Vet Pathol 2024; 61:357-365. [PMID: 37937724 PMCID: PMC11067406 DOI: 10.1177/03009858231209408] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2023]
Abstract
Sarcoids are common mesenchymal neoplasms of horses. Although there are few studies in which sarcoids have been followed over a long period of time, sarcoids are considered locally invasive and have been reported to frequently recur following surgical excision. Currently, no histological features have been identified to predict which sarcoids will recur after excision. The present study comprised 49 sarcoids for which histology sections were available and in which the recurrence status of the case was known. Each sarcoid was excised from a different horse. Overall, 12 of the 49 (24%) sarcoids recurred after surgical excision. Mitotic count (MC), cellularity, necrosis, nuclear pleomorphism, and inflammation of the sarcoids were evaluated histologically. Of these, MC correlated with recurrence. Four of 5 (80%) sarcoids with an MC ≥ 20 in 2.37 mm2 recurred, which was a significantly higher recurrence rate than that of sarcoids with an MC < 20, 8 of 44 cases recurred (18%), P = .0051. Clinical type was also found to correlate with recurrence. Three of 4 (75%) fibroblastic types recurred, which was a significantly higher recurrence rate than that of sarcoids with other clinical types, 9 of 45 cases (18%), P < .001. In addition, univariate Cox regression analysis confirmed fibroblastic type and MC ≥ 20 as significant predictors for recurrence (P = .016 and P = .005, respectively). To the authors' knowledge, this is the first large study examining recurrence rates in sarcoids, and the first time that histological features have been correlated with recurrence.
Collapse
Affiliation(s)
| | | | - Geoff Orbell
- Gribbles Veterinary, Palmerston North, New Zealand
| | | | | |
Collapse
|
2
|
Offer KS, Dixon CE, Sutton DGM. Treatment of equine sarcoids: A systematic review. Equine Vet J 2024; 56:12-25. [PMID: 36917551 DOI: 10.1111/evj.13935] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/24/2022] [Accepted: 03/09/2023] [Indexed: 03/15/2023]
Abstract
BACKGROUND The sarcoid is the most common equine cutaneous neoplasm. Evidence-based treatment of this condition is often lacking, and selection of treatment modality based on clinical experience or anecdotal evidence. OBJECTIVES To assess the quality of the currently available best evidence regarding the treatment of the equine sarcoid. STUDY DESIGN Systematic review. METHODS In compliance with PRISMA guidelines, literature searches were performed in PUBMED, Web of Science, CAB Abstracts, EMBASE (Ovid) and Scopus in April 2021. Included papers were required to describe an interventional study examining sarcoid treatment strategy, of level 4 evidence or greater. The case definition required confirmation of at least some included lesions on histopathology, and a minimum of 6 months of follow-up was required on treated cases. Studies were assessed by two independent reviewers (KO, CD). Data extraction was performed manually, followed by risk of bias assessment. Methodological quality was assessed using the GRADE system. RESULTS In total, 10 studies were included in the review. Case definition was confirmed via histopathology in all included lesions in 60% of papers. Time to follow-up was variably reported. Overall risk of bias ranged from 'some concerns' to 'critical'. Reported sarcoid regression rate ranged from 28% to 100% on an individual sarcoid level, and 9%-100% on a whole horse level. Transient local inflammation was reported following most treatment strategies, with further adverse events reported infrequently. MAIN LIMITATIONS Review methodology excluded a large proportion of available literature regarding the equine sarcoid. Significant heterogeneity between included studies prevented quantitative synthesis and most included papers were at significant risk of bias, indirectness, and imprecision. CONCLUSIONS There is insufficient evidence currently available to recommend one sarcoid treatment over another. There is an urgent need for sufficiently powered, randomised, placebo-controlled trials in order to allow more definitive comparison of the efficacy of different treatment strategies.
Collapse
Affiliation(s)
- Katie S Offer
- School of Biodiversity, One Health and Veterinary Medicine, College of Medical Veterinary and Life Sciences, University of Glasgow, Glasgow, UK
| | - Claire E Dixon
- Tufts Equine Center at the Hospital for Large Animals, Cummings School of Veterinary Medicine at Tufts University, North Grafton, Massachusetts, USA
| | - David G M Sutton
- School of Biodiversity, One Health and Veterinary Medicine, College of Medical Veterinary and Life Sciences, University of Glasgow, Glasgow, UK
| |
Collapse
|
3
|
Curnow B, Rich AF, Ireland J, Correa DC, Dunn J, Jenkins D, Carslake H, Ressel L. Histological evidence of superficial inflammation is associated with lower recurrence of equine sarcoids following surgical removal: A follow-up study of 106 tumours in 64 horses. Vet J 2023; 292:105953. [PMID: 36775186 DOI: 10.1016/j.tvjl.2023.105953] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/26/2021] [Revised: 01/31/2023] [Accepted: 02/08/2023] [Indexed: 02/12/2023]
Abstract
Although the equine sarcoid is the most common skin neoplasm in domesticated horses, histopathological characteristics have not previously been evaluated for association with recurrence. The aim of this retrospective cohort study was to investigate clinical and histopathological features of excised equine sarcoids and to evaluate their association with recurrence at the original surgical site and at new sites. Clinical records and excisional biopsies from 106 equine sarcoids from 64 horses referred to Leahurst Equine Hospital, University of Liverpool, between March 2010 and February 2015 were retrieved. Biopsies were re-evaluated histologically. Clinical data were obtained from hospital records, and owner-reported follow-up data were obtained by telephone questionnaire. Associations between clinical and histopathological features of sarcoids and their recurrence at the surgical site were determined using uni- and multivariable mixed effects logistic regression. Recurrence of sarcoids at the surgical site occurred in 30 horses (46.9%). Sarcoids developed at a distant site in 21 horses (32.8%). In the final mixed effects logistic regression model, only superficial inflammation was associated with reduced odds of recurrence at the surgical site (adjusted odds ratio, 0.32; 95% confidence intervals, 0.10-0.96; P = 0.04). This suggests that the inflammatory process may play a role in protecting horses against the recurrence of sarcoids.
Collapse
Affiliation(s)
- B Curnow
- Department of Equine Clinical Science, University of Liverpool, Leahurst Campus, Neston CH64 7TE, UK.
| | - A F Rich
- Department of Veterinary Anatomy, Physiology and Pathology, Institute of Infection, Veterinary and Ecological Sciences, University of Liverpool, Leahurst Campus, Neston CH64 7TE, UK
| | - J Ireland
- Department of Equine Clinical Science, University of Liverpool, Leahurst Campus, Neston CH64 7TE, UK
| | - D Cubillos Correa
- Department of Veterinary Anatomy, Physiology and Pathology, Institute of Infection, Veterinary and Ecological Sciences, University of Liverpool, Leahurst Campus, Neston CH64 7TE, UK
| | - J Dunn
- Department of Equine Clinical Science, University of Liverpool, Leahurst Campus, Neston CH64 7TE, UK
| | - D Jenkins
- Department of Equine Clinical Science, University of Liverpool, Leahurst Campus, Neston CH64 7TE, UK
| | - H Carslake
- Department of Equine Clinical Science, University of Liverpool, Leahurst Campus, Neston CH64 7TE, UK
| | - L Ressel
- Department of Veterinary Anatomy, Physiology and Pathology, Institute of Infection, Veterinary and Ecological Sciences, University of Liverpool, Leahurst Campus, Neston CH64 7TE, UK
| |
Collapse
|
4
|
Hollis AR. Management of equine sarcoids. Vet J 2023; 291:105926. [PMID: 36334801 DOI: 10.1016/j.tvjl.2022.105926] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/24/2020] [Revised: 10/19/2022] [Accepted: 10/29/2022] [Indexed: 12/12/2022]
Abstract
Sarcoids are the most common cutaneous neoplasm of the horse, arising as a result of a neoplastic proliferation of fibroblasts associated with infection with bovine papillomavirus, most notably types 1 and 2. Although they do not metastasise, they are locally invasive and aggressive, and can lead to important welfare concerns, interfere with tack and therefore impede athleticism, and undoubtedly lead to a reduction in the value of affected horses. This review discusses the evidence behind the most commonly used treatments for equine sarcoids. The most commonly used treatments are discussed. No one treatment is universally successful, and there are many treatments with varying level of scientific evaluation and reported success rates.
Collapse
Affiliation(s)
- Anna R Hollis
- Cambridge Equine Hospital, Department of Veterinary Medicine, University of Cambridge, Madingley Road, Cambridge CB3 0ES, UK.
| |
Collapse
|
5
|
Meurice A, Pujol R, Albaric O, De Fourmestraux C, Tessier C. Tracheal obstructive mastocytoma in a pony. EQUINE VET EDUC 2022. [DOI: 10.1111/eve.13703] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Affiliation(s)
- Antoine Meurice
- Department of Surgery, Equine Clinic, ONIRIS, National College of Veterinary Medicine Food Science and Engineering Nantes France
| | - Raymond Pujol
- Department of Surgery, Equine Clinic, ONIRIS, National College of Veterinary Medicine Food Science and Engineering Nantes France
| | - Olivier Albaric
- LabOniris, ONIRIS, National College of Veterinary Medicine Food Science and Engineering Nantes France
| | - Claire De Fourmestraux
- Department of Surgery, Equine Clinic, ONIRIS, National College of Veterinary Medicine Food Science and Engineering Nantes France
| | - Caroline Tessier
- Department of Surgery, Equine Clinic, ONIRIS, National College of Veterinary Medicine Food Science and Engineering Nantes France
| |
Collapse
|
6
|
Saba C, Eggleston R, Parks A, Peroni J, Sjoberg E, Rice S, Tyma J, Williams J, Grosenbaugh D, Leard AT. ALVAC-fIL2, a feline interleukin-2 immunomodulator, as a treatment for sarcoids in horses: A pilot study. J Vet Intern Med 2022; 36:1179-1184. [PMID: 35416353 PMCID: PMC9151478 DOI: 10.1111/jvim.16425] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/26/2021] [Revised: 03/16/2022] [Accepted: 03/25/2022] [Indexed: 12/19/2022] Open
Abstract
Background Sarcoid tumors are common in horses and may negatively impact the performance and value of the horse. No known treatment is reliably successful. Hypotheses/Objectives To determine tolerability, overall response rate, time to response, and progression‐free survival of horses with biopsy‐confirmed or suspected sarcoids treated with ALVAC‐fIL2. Animals Client‐owned horses with measurable, presumed‐ or biopsy‐confirmed sarcoid tumors. Methods Prospective pilot study. One milliliter of ALVAC‐fIL2 was injected into 4 to 5 areas of the sarcoid(s) in each horse (week 0); this treatment was repeated in weeks 1, 3, and 7. Sarcoids were measured at each visit, and response to treatment was determined according to the Response Evaluation Criteria in Solid Tumors for dogs (v1.0). After the final treatment, horses were reassessed and sarcoids remeasured every 3 months until tumor progression or for a minimum of 1 year if progression was not documented. Results Fourteen horses were included. Tumor size decreased in 86% of the horses, and the median time to first response was 89 days (range, 34‐406 days). Median time to best response was 211 days (range, 56‐406 days), but 3 of the sarcoids still were decreasing in size at the time of final evaluation. The median progression‐free interval was not reached. Adverse events were minimal and included transient focal inflammation in 2 horses. Conclusions and Clinical Importance Intratumoral injection of ALVAC‐fIL2 has promise as a well‐tolerated and effective, tissue‐sparing treatment for horses with sarcoid tumors.
Collapse
Affiliation(s)
- Corey Saba
- Department of Large Animal Medicine and Surgery, University of Georgia College of Veterinary Medicine, Athens, Georgia, USA
| | - Randall Eggleston
- Department of Large Animal Medicine and Surgery, University of Georgia College of Veterinary Medicine, Athens, Georgia, USA
| | - Andrew Parks
- Department of Large Animal Medicine and Surgery, University of Georgia College of Veterinary Medicine, Athens, Georgia, USA
| | - John Peroni
- Department of Large Animal Medicine and Surgery, University of Georgia College of Veterinary Medicine, Athens, Georgia, USA
| | - Eric Sjoberg
- Maggie's Menagerie Veterinary Services, Ila, Georgia, USA
| | - Shelbe Rice
- Maggie's Menagerie Veterinary Services, Ila, Georgia, USA
| | - Jesse Tyma
- Department of Large Animal Medicine and Surgery, University of Georgia College of Veterinary Medicine, Athens, Georgia, USA
| | - Jarred Williams
- Department of Large Animal Medicine and Surgery, University of Georgia College of Veterinary Medicine, Athens, Georgia, USA
| | | | | |
Collapse
|
7
|
Biermann NM, Doyle AJ, Hanna P, Stoughton WB. Acute hindlimb paresis caused by extension of a peripheral nerve sheath tumour into the spinal canal of a horse. EQUINE VET EDUC 2021. [DOI: 10.1111/eve.13560] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
Affiliation(s)
- N. M. Biermann
- Department of Health Management Atlantic Veterinary College University of Prince Edward Island Charlottetown Canada
| | - A. J. Doyle
- Department of Health Management Atlantic Veterinary College University of Prince Edward Island Charlottetown Canada
| | - P. Hanna
- Department of Pathology and Microbiology Atlantic Veterinary College University of Prince Edward Island Charlottetown Canada
| | - W. B. Stoughton
- Department of Health Management Atlantic Veterinary College University of Prince Edward Island Charlottetown Canada
| |
Collapse
|
8
|
Palozzo A, Celani G, Varasano V, Marruchella G, Petrizzi L. Surgical Debulking and TransEndoscopic Noncontact Diode Laser Application for Treating a Sinonasal Myxoma in a Horse. J Equine Vet Sci 2020; 98:103354. [PMID: 33663730 DOI: 10.1016/j.jevs.2020.103354] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/08/2020] [Revised: 12/07/2020] [Accepted: 12/07/2020] [Indexed: 11/15/2022]
Abstract
Equine sinonasal myxomas (SNM) are very rare; only a few cases/small case series are reported in veterinary literature. The purpose of this report is to describe the diagnostic and surgical procedure adopted to approach the neoplastic mass in a case of equine SNM. A 5 year old, Murgese gelding was presented with mild serous nasal discharge, minimal facial swelling, decreased airflow from the right nostril, and dull frontal sinus percussion. Diagnostic imaging, including endoscopy, revealed a pale mass in the caudal portion of the right middle meatus, which developed inside the right conchofrontal sinus and nasal cavity and deviated the nasal septum to the left side. A large frontonasal bone flap was created with the horse in general anesthesia, aiming to remove the lesion and perform further diagnostic investigation. The mass had the shape of a small orange, the caudodorsal and rostral part having a hard wall, whereas the ventral part being friable; the inside was hollow, containing a viscous and transparent liquid. Surgical excision was broad but incomplete, and therefore after surgery, a standing transendoscopic diode laser irradiation and photoablation of small residual lesions per nasum were performed. Microscopically, the mass consisted of spindle-shaped cells, loosely arranged within an abundant, light blue myxoid matrix. On the basis of clinical and pathologic findings, the diagnosis of sinonasal myxoma was made. Although benign and slowly growing, myxomas usually tend to infiltrate the surrounding tissues; as a consequence, recurrence is very likely after surgical excision. In the case described herein, the combination of a surgical excision, transendoscopic diode laser irradiation, and photoablation provided a positive outcome, until at least 14 months after surgery.
Collapse
Affiliation(s)
- Adriana Palozzo
- Unit of Equine Medicine and Surgery, Veterinary Teaching Hospital, Faculty of Veterinary Medicine of the University of Teramo, Italy.
| | - Gianluca Celani
- Unit of Equine Medicine and Surgery, Veterinary Teaching Hospital, Faculty of Veterinary Medicine of the University of Teramo, Italy
| | - Vincenzo Varasano
- Unit of Equine Medicine and Surgery, Veterinary Teaching Hospital, Faculty of Veterinary Medicine of the University of Teramo, Italy
| | - Giuseppe Marruchella
- Unit of Equine Medicine and Surgery, Veterinary Teaching Hospital, Faculty of Veterinary Medicine of the University of Teramo, Italy
| | - Lucio Petrizzi
- Unit of Equine Medicine and Surgery, Veterinary Teaching Hospital, Faculty of Veterinary Medicine of the University of Teramo, Italy
| |
Collapse
|
9
|
Jansson J, Knottenbelt D, Hennessy S. Use of random pattern skin flaps for wound closure in two horses. EQUINE VET EDUC 2020. [DOI: 10.1111/eve.13423] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Affiliation(s)
- J. Jansson
- Lisadell Equine Hospital Navan Co. Meath Ireland
| | | | - S. Hennessy
- Lisadell Equine Hospital Navan Co. Meath Ireland
| |
Collapse
|
10
|
Knottenbelt DC. The Equine Sarcoid: Why Are There so Many Treatment Options? Vet Clin North Am Equine Pract 2019; 35:243-262. [PMID: 31097356 DOI: 10.1016/j.cveq.2019.03.006] [Citation(s) in RCA: 20] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/08/2023] Open
Abstract
This article discusses the main treatments for sarcoid and the specific difficulties of these. It explains to some extent why the frustrations of a condition for which there is no single treatment option have led to the burgeoning of an industry of irrational treatments. The factors that need to be considered before selecting an option for treatment are wider than is the case in most other disease entities as a result of the complexity of the condition, its variable phenotypes, and the individual perceptions and experiences of both veterinarians and owners.
Collapse
Affiliation(s)
- Derek C Knottenbelt
- Equine Medical Solutions Ltd, STEP Building, Kildean Business & Enterprise Hub, 146 Drip Road, Stirling, Scotland, FK8 1RW, UK.
| |
Collapse
|
11
|
Koch C, Martens A, Hainisch E, Schüpbach G, Gerber V, Haspeslagh M. The clinical diagnosis of equine sarcoids — Part 1: Assessment of sensitivity and specificity using a multicentre case-based online examination. Vet J 2018; 242:77-82. [DOI: 10.1016/j.tvjl.2018.08.009] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/16/2018] [Revised: 07/05/2018] [Accepted: 08/31/2018] [Indexed: 10/28/2022]
|